Ustekinumab is a fully human, monoclonal antibody that binds to the interleukin(IL)-12/IL-23 p40 subunit. There are several reports of anti-TNF-α agent induced interstitial lung disease and autoimmune thyroiditis. However, there was only one case of interstitial lung disease associated with ustekinumab. Furthermore, ustekinumab induced autoimmune thyroiditis has not been reported yet. A 68-year-old woman presented with a 7-year history of psoriasis. She had been consecutively treated with methotrexate, cyclosporine and narrow band UVB for 2 years, however PASI score remained above 12. Then, ustekinumab was started and PASI score dramatically reduced to less than 4 after 3 injections. After 5 injections, the patient complained of dyspnea, so she was referred to a pulmonologist and chest CT was performed. The patient was diagnosed with interstitial lung disease and enlargement of thyroid gland was found on chest CT. The patient was diagnosed with Graves’ disease through further thyroid function tests including autoantibodies, thyroid ultrasonography and scanning. After discontinuation of ustekinumab, respiratory symptoms were improved and thyroid hormone levels were normalized. These findings suggested that interstitial lung disease and autoimmune thyroiditis were associated with ustekinumab. Herein, we report a case of interstitial lung disease and autoimmune thyroiditis associated with ustekinumab, further studies will be needed.